Waters Tim Riley on Developing Business in Proteomics, Metabolomics | GenomeWeb

Tim Riley has been involved with the commercialization of mass spectrometry instrumentation since 1984 when he joined VG Instruments, which was acquired by Fisons Instruments in 1990, and then spun off as Micromass in 1996. Then, in 1997, Waters purchased Micromass and Riley served as president of the US sales and services division. Currently, Riley is vice president of proteomics business development for Waters. BioCommerce Week spoke to Riley recently to get a view of the company’s business development strategy for proteomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.